Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Understanding idiopathic intracranial hypertension : mechanisms, management, and future directions. / Markey, Keira A; Mollan, Susan P; Jensen, Rigmor H; Sinclair, Alexandra J.
I: Lancet Neurology, Bind 15, Nr. 1, 01.2016, s. 78-91.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Understanding idiopathic intracranial hypertension
T2 - mechanisms, management, and future directions
AU - Markey, Keira A
AU - Mollan, Susan P
AU - Jensen, Rigmor H
AU - Sinclair, Alexandra J
N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.
PY - 2016/1
Y1 - 2016/1
N2 - Idiopathic intracranial hypertension is a disorder characterised by raised intracranial pressure that predominantly affects young, obese women. Pathogenesis has not been fully elucidated, but several causal factors have been proposed. Symptoms can include headaches, visual loss, pulsatile tinnitus, and back and neck pain, but the clinical presentation is highly variable. Although few studies have been done to support evidence-based management, several recent advances have the potential to enhance understanding of the causes of the disease and to guide treatment decisions. Investigators of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) reported beneficial effects of acetazolamide in patients with mild visual loss. Studies have also established weight loss as an effective disease-modifying treatment, and further clinical trials to investigate new treatments are underway. The incidence of idiopathic intracranial hypertension is expected to increase as rates of obesity increase; efforts to reduce diagnostic delays and identify new, effective approaches to treatment will be key to meeting the needs of a growing number of patients.
AB - Idiopathic intracranial hypertension is a disorder characterised by raised intracranial pressure that predominantly affects young, obese women. Pathogenesis has not been fully elucidated, but several causal factors have been proposed. Symptoms can include headaches, visual loss, pulsatile tinnitus, and back and neck pain, but the clinical presentation is highly variable. Although few studies have been done to support evidence-based management, several recent advances have the potential to enhance understanding of the causes of the disease and to guide treatment decisions. Investigators of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) reported beneficial effects of acetazolamide in patients with mild visual loss. Studies have also established weight loss as an effective disease-modifying treatment, and further clinical trials to investigate new treatments are underway. The incidence of idiopathic intracranial hypertension is expected to increase as rates of obesity increase; efforts to reduce diagnostic delays and identify new, effective approaches to treatment will be key to meeting the needs of a growing number of patients.
KW - Animals
KW - Comprehension
KW - Disease Management
KW - Forecasting
KW - Humans
KW - Intracranial Hypertension
KW - Obesity
KW - Pseudotumor Cerebri
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
KW - Review
U2 - 10.1016/S1474-4422(15)00298-7
DO - 10.1016/S1474-4422(15)00298-7
M3 - Review
C2 - 26700907
VL - 15
SP - 78
EP - 91
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 1
ER -
ID: 179045050